Citadel Advisors - VANDA PHARMACEUTICALS INC ownership

VANDA PHARMACEUTICALS INC's ticker is VNDA and the CUSIP is 921659108. A total of 128 filers reported holding VANDA PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 7.96 and the average weighting 0.2%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of VANDA PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$2,990,101
-29.4%
692,153
+7.7%
0.00%0.0%
Q2 2023$4,234,168
-39.0%
642,514
-37.2%
0.00%
-50.0%
Q1 2023$6,942,103
+64.4%
1,022,401
+78.9%
0.00%
+100.0%
Q4 2022$4,223,599
+387.2%
571,529
+551.4%
0.00%
Q3 2022$867,000
+26.0%
87,735
+38.9%
0.00%
Q2 2022$688,000
+89.5%
63,177
+96.8%
0.00%
Q1 2022$363,000
-67.7%
32,100
-55.2%
0.00%
Q4 2021$1,124,000
-13.9%
71,600
-6.0%
0.00%
Q3 2021$1,306,000
-56.1%
76,200
-45.0%
0.00%
-100.0%
Q2 2021$2,978,000
+2.5%
138,424
-28.4%
0.00%0.0%
Q1 2021$2,905,000
-9.4%
193,449
-20.7%
0.00%0.0%
Q4 2020$3,205,000
-66.5%
243,975
-75.4%
0.00%
-66.7%
Q3 2020$9,570,000
-7.9%
990,735
+9.0%
0.00%
-25.0%
Q2 2020$10,395,000
+214.6%
908,651
+185.0%
0.00%
+300.0%
Q1 2020$3,304,000
-41.1%
318,876
-6.7%
0.00%
-50.0%
Q4 2019$5,606,000
+2.1%
341,634
-17.4%
0.00%
-33.3%
Q3 2019$5,490,000
+657.2%
413,441
+703.3%
0.00%
Q2 2019$725,000
-77.6%
51,467
-70.8%
0.00%
-100.0%
Q1 2019$3,238,000
-35.5%
176,004
-8.5%
0.00%
-66.7%
Q4 2018$5,024,000
-53.0%
192,250
-58.8%
0.00%
-25.0%
Q3 2018$10,697,000
+297.4%
466,099
+229.8%
0.00%
+300.0%
Q2 2018$2,692,000
+77.0%
141,320
+56.5%
0.00%0.0%
Q1 2018$1,521,000
-30.3%
90,314
-37.1%
0.00%0.0%
Q4 2017$2,182,000
-85.3%
143,600
-82.7%
0.00%
-91.7%
Q3 2017$14,873,000
+79.0%
830,885
+63.0%
0.01%
+71.4%
Q2 2017$8,307,000
+33.4%
509,618
+14.6%
0.01%
+16.7%
Q1 2017$6,225,000
+115.2%
444,685
+145.2%
0.01%
+100.0%
Q4 2016$2,893,000
+60.5%
181,383
+67.4%
0.00%
+50.0%
Q3 2016$1,803,000
+819.9%
108,323
+519.3%
0.00%
Q2 2016$196,000
-61.4%
17,492
-71.2%
0.00%
-100.0%
Q1 2016$508,000
-50.3%
60,743
-44.7%
0.00%0.0%
Q4 2015$1,022,000
-32.6%
109,815
-18.3%
0.00%0.0%
Q3 2015$1,516,000
+12.4%
134,400
+26.4%
0.00%0.0%
Q2 2015$1,349,000
+222.7%
106,293
+136.5%
0.00%
Q1 2015$418,000
-64.3%
44,947
-45.0%
0.00%
-100.0%
Q4 2014$1,170,000
+7212.5%
81,677
+5203.7%
0.00%
Q3 2014$16,000
-97.3%
1,540
-95.8%
0.00%
-100.0%
Q2 2014$593,000
-48.3%
36,650
-48.0%
0.00%0.0%
Q1 2014$1,146,000
-75.8%
70,519
-81.5%
0.00%
-83.3%
Q4 2013$4,736,000
+615.4%
381,637
+532.2%
0.01%
+500.0%
Q3 2013$662,000
-11.6%
60,362
-34.9%
0.00%0.0%
Q2 2013$749,00092,6560.00%
Other shareholders
VANDA PHARMACEUTICALS INC shareholders Q4 2017
NameSharesValueWeighting ↓
Palo Alto Investors LP 2,491,200$27,154,0002.37%
Profit Investment Management, LLC 281,890$3,071,0002.26%
Sio Capital Management, LLC 488,965$5,330,0002.00%
Zebra Capital Management LLC 14,766$161,0000.47%
Prairiewood Capital, LLC 50,165$547,0000.43%
TANG CAPITAL MANAGEMENT LLC 256,696$2,798,0000.42%
HUSSMAN STRATEGIC ADVISORS, INC. 156,000$1,700,0000.29%
GLOBEFLEX CAPITAL L P 100,843$1,099,0000.27%
Epoch Investment Partners, Inc. 2,757,646$30,059,0000.18%
EMC Capital Management 16,185$176,0000.15%
View complete list of VANDA PHARMACEUTICALS INC shareholders